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ABSTRACT 
Background: Sustained positive outcomes after coronary artery bypass grafting (CABG) requires risk factor modifica-
tion and secondary prevention medications. Much attention has been focused on planning at hospital discharge; how-
ever longer-term patient compliance is not well described. Hypothesis: A follow-up multidisciplinary educational pro-
gram improves disease understanding, motivation to reduce cardiovascular risk, and secondary prevention medication 
prescribing following hospital discharge. Methods: Using a prospective, randomized, controlled design, patients un-
dergoing CABG completed surveys over a year period, assessing disease understanding and motivation. Four to six 
weeks after CABG, intervention subjects completed a one-time educational program with a multidisciplinary team. The 
primary endpoint was a composite score of reduced risk factors, medication use, and awareness of prescribed medica-
tions. Secondary endpoints evaluated survey scores and medication use rates. Wilcoxon Rank Sum and Chi Square tests 
compared data between specific time points. Generalized estimating equations and linear contrasts of the parameter 
estimates compared data at the three time points. Results: The final analysis included 98 subjects (Intervention = 49, 
Control = 49). The composite score was not different between groups (I = 12.8 ± 4.5 points, C = 12.7 ± 4.9 points, p = 
0.9405). Improvements were noted in understanding and motivation in the entire cohort, but these changes were not 
influenced by the intervention. Medication prescribing declined at 3 and 12 months after CABG without significant 
differences between the groups. Conclusions: Disease understanding, motivation to reduce risk, and medication use are 
robust at hospital discharge but the latter declines with time and was not improved by our intervention. These findings 
are concerning and warrant further study. 
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1. Introduction 
Advances in surgical techniques have resulted in excel-
lent postoperative outcomes from coronary artery bypass 
grafting (CABG) operations, despite the high acuity of 
patients in the current era [1,2]. Since coronary artery 
disease (CAD) is a chronic, progressive illness, optimal 
postoperative treatment of these patients should include 
preventive measures that have been demonstrated to limit 
future cardiovascular events, subsequent need for inter-
ventions, and improve outcomes [3-5]. Since an optimal 
prevention regimen is critical to achieving long-term 
success, systems of care should adopt integrative and 
multidisciplinary methodologies to assure that patients 
receive an ongoing benefit from CABG operations, with 
early initiation after the surgical procedure [6]. 
Previous studies have documented that patient com- 
pliance with secondary prevention regimens after CABG 
has often been inadequate, especially in relation to the 
four major drug classes that have been shown to be par-
ticularly efficacious (platelet inhibitors, beta blockers, 
lipid-lowering agents, and angiotensin converting en- 
zyme inhibitors (ACEIs) or angiotensin II receptor blo- 
ckers (ARBs) [7-13]. Recently, a large multicenter trial, 
utilizing patients included in the Society of Thoracic 
Surgeons (STS) database, showed that local “low-inten- 
sity” continuous quality improvement protocols designed 
to reinforce preventive strategies were very effective at 
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assuring that postoperative patients were discharged from 
the hospital on an appropriate drug regimen [14]. It re- 
mains unclear if efforts focused solely on the time of 
hospital discharge are sufficient to affect longer-term 
compliance with these important measures [15]. The ob-
jective of this randomized, controlled study was to assess 
the influence of a multidisciplinary follow-up educa-
tional program on disease understanding, motivation to 
reduce cardiovascular risk, and secondary prevention 
medication prescribing following CABG. 
2. Methods 
2.1. Patient Population 
Between January 2008 and January 2009, patients who 
underwent CABG at our institution were offered inclu-
sion in this secondary prevention study. Patients who 
accepted entrance into the study and completed the entire 
program comprise the subject of this analysis. The study 
was approved by our Institutional Review Board and 
each patient gave informed consent. 
2.2. Study Design 
As standard care, all patients received instruction by 
teams of specialists during the postoperative recovery 
phase prior to hospital discharge. This included the inpa-
tient cardiac rehabilitation team that stressed the impor-
tance of prevention, specifically physical activity. Addi-
tionally, each patient was counseled by a dietician and 
every patient who reported a tobacco use history was 
provided smoking cessation counseling. The cardiac sur-
gical team, specifically physician assistants, was charged 
with prescribing indicated preventive medications (anti- 
platelet agents, statins, beta blockers, and ACEI/ARBs) 
prior to hospital discharge if the patient was eligible for 
the medication. 
During the postoperative period, we randomized sub-
jects to an intervention or control (“usual care”) group 
using a computer generated randomization scheme and 
sealed envelopes. Hypothesizing that hospital discharge 
might not be the optimal time to deliver an educational 
message to anxious postoperative patients and their fami-
lies; we examined the effects of an additional educational 
intervention 4 - 6 weeks following the hospitalization. 
This intervention, conducted by a multidisciplinary team 
consisting of a pharmacist, dietician, and cardiac reha-
bilitation nurse, was designed to be an educational 
“booster” to reinforce the importance of secondary pre-
vention, answer patient questions or concerns, and thereby 
increase understanding of evidence-based methods of 
prevention. 
The “booster” consisted of a 3 hour intervention that 
included a general information group session accompa-
nied by individually-tailored 30 minute meetings with 3 
individual clinicians: each discipline was represented by 
1 or 2 trained individuals throughout the study time pe-
riod and discussions were initially scripted to attain the 
most consistency possible. None of the professional par-
ticipants in the “booster” were involved in the patient 
selection, follow-up, data analysis, or overall conduct of 
the study. A plan of care was formulated and given in 
writing to the patient, his/her cardiologist and their pri-
mary care physician. No medication changes were or-
dered during the “booster”, but rather modifications were 
suggested to the referring physicians so that appropriate 
follow up and monitoring could be completed. Family 
participation was strongly encouraged during the “booster” 
sessions in order to enhance the quality of the interaction 
between the patient and the individual specialists. Data 
were collected by study coordinators at 3 distinct time 
points: hospital discharge (DC), and then at the 3 and 12 
month intervals following hospital discharge. Demo-
graphics, clinical parameters, and medication-use data 
were obtained from the hospital’s electronic medical re-
cord and outpatient clinic records.  
2.3. Study Outcomes 
The electronic medical record was used to determine 
medication use rates at the three study time points and 
was compared between the groups. Medication use is 
reported as percent use among those eligible to receive 
the therapy. Eligibility was determined by the variables 
provided in Box 1. For medication use data, note that 
patients might have relative contraindications at the 
baseline time point (hospital discharge), that no longer 
existed at the 3 and 12 month time periods (for example, 
hypotension). Thus, more patients were considered eligi-
ble at the 3 and 12 month time points. 
In order to comprehensively assess the efficacy of the 
“booster” intervention, we devised a Composite Heart 
Health Index (CHHI), which took into account im-
provement in risk factor parameters, indicated medica-
tion use, the patient’s awareness regarding their disease 
and prescribed medications. The variables used to calcu-
late the score are presented in Table 1. Points were 
awarded when improvement was shown in risk factors 
(such as smoking status, body mass index, lipid levels, 
and blood pressure) between the time intervals. Points 
were also awarded when patients could correctly identify 
if they were or were not taking specific medications for 
secondary prevention. Points were deducted however 
when these medications were not prescribed to eligible 
patients. Scores from a 15 question “understanding” sur-
vey and a 6 question “motivation” survey were assessed.  
The written surveys were administered during each of 
the three study time points. We divided the number of 
survey questions answered correctly by the number of 
survey questions answered and multiplied this value by  
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 Aspirin 
Indications: 
 All patients undergoing CABG 
 
Contraindications: 
 Allergy or intolerance 
 Bleeding (active or recent history) 
 Other anticoagulation / antiplatelet chosen 
 Thrombocytopenia 




 All patients undergoing CABG 
 
Contraindications: 
 Allergy or intolerance 
 Clinically significant bradycardia or systemic hypotension 
 Bronchospastic disease (asthma or COPD with 
bronchospasm ) 
 Heart failure (decompensated, NYHA IV) 
 Cardiogenic shock 
 Cardiac conduction abnormality 
 Peripheral vascular disease 
 Pulmonary edema 




 History of myocardial infarction 
 Reduced preoperative ejection fraction (<0.40)  
 
Contraindications: 
 Allergy or intolerance 
 Hyperkalemia (serum potassium > 5.5) 
 Clinically significant systemic hypotension 
 Acute renal failure 
 Renal artery stenosis (bilateral and unstented) 
 Aortic valve stenosis 
 Pregnancy 




 All patients undergoing CABG 
 
Contraindications: 
 Allergy or intolerance 
 Liver disease (elevation LFTs or history of ESLD) 
 History of statin induced muscle soreness/myopathy 
 History of statin induced rhabdomyolysis 
 Severe co-morbid illness /end of life status 
 
Box 1. Indications and contraindications to secondary pre-
vention medications after coronary artery bypass graft sur- 
gery (CABG). 
100 to obtain a survey score for both the understanding 
and motivation surveys. 
2.4. Statistical Methods 
The mean composite score and survey scores at the three  
Table 1. Calculation of the Composite Heart Health Index 
(possible range –8 to 26 points). 
Points Variables 
1 Stopped smoking between d/c and 3 months 
1 Stopped smoking between 3 and 12 months 
1 Decreased BMI between d/c and 3 months 
1 Decreased BMI between 3 and 12 months 
1 Decreased MAP between d/c and 3 months 
1 Decreased MAP between 3 and 12 months 
1 Decreased LDL between d/c and 3 months 
1 Decreased LDL between 3 and 12 months 
1 Increased HDL between d/c and 3 months 
1 Increased HDL between 3 and 12 months 
1 Decreased triglycerides between d/c and 3 months 
1 Decreased triglycerides between 3 and 12 months 
Prescribed ASA at 3 months 
(0 points for those with contraindications) 
1 
Prescribed BB at 3 months 
(0 points for those with contraindications) 
1 
Prescribed ACEI/ARB at 3 months 
(0 points for those with contraindications) 
1 
1 
Prescribed STATINS at 3 months 
(0 points for those with contraindications) 
–1 Eligible but NOT prescribed ASA at 3 months 
–1 Eligible but NOT prescribed BB at 3 months 
–1 Eligible but NOT prescribed ACEI/ARB at 3 months 
–1 Eligible but NOT prescribed STATINS at 3 months 
Prescribed ASA at 12 months 
(0 points for those with contraindications) 
1 
Prescribed BB at 12 months 
(0 points for those with contraindications) 
1 
Prescribed ACEI/ARB at 12 months 
(0 points for those with contraindications) 
1 
1 
Prescribed STATINS at 12 months 
(0 points for those with contraindications) 
–1 Eligible but NOT prescribed ASA at 12 months 
–1 Eligible but NOT prescribed BB at 12 months 
–1 Eligible but NOT prescribed ACEI/ARB at 12 months 
–1 Eligible but NOT prescribed STATINS at 12 months 
1 
Understood if they were or were not 
currently prescribed ASA at 3 months 
1 
Understood if they were or were not 
currently prescribed BB at 3 months 
1 
Understood if they were or were not 
currently prescribed STATINS at 3 months 
1 
Understood if they were or were not 
currently prescribed ASA at 12 months 
1 
Understood if they were or were not 
currently prescribed BB at 12 months 
1 
Understood if they were or were not 
currently prescribed STATINS at 12 months 
Abbreviations: COPD, chronic obstructive pulmonary disease; NYHA, New 
York Heart Association; LFTs, liver function tests; ESLD, end stage liver 
disease; d/c = discharge from hospital; BMI = body mass index; MAP = 
mean arterial blood pressure; LDL = low-density lipoprotein; HDL = high- 
density lipoprotein: ASA = aspirin; BB = beta blockers; ACEI = angiotensin- 
converting enzyme inhibitors; ARB = angiotensin II receptor blockers. 
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time points were compared between the groups using a 
Wilcoxon Rank Sum test. Differences between medica-
tion use at specific time points, and other categorical data 
were compared with Chi square or Fisher’s exact tests. 
To compare the statistically dependent understanding and 
motivation survey scores at the different time points we 
used generalized estimating equations (GEE), to account 
for the correlated responses from the same subjects. Lin-
ear contrasts of the parameter estimates were performed 
to do pairwise comparisons between the three time points 
using Wald chi square tests. Alpha was set a priori at 0.05. 
3. Results 
3.1. Population 
During the study period 118 subjects (ages 42 to 86 year 
old) were screened, offered admission, and eventually 
consented to participate in this research project. These 
patients were randomized into the “usual care” and in-
tervention (“booster”) groups. Patients who were unable 
or unwilling to complete the 3 surveys were dropped 
from the study. Of the original group of 118, 98 (49 in 
each group) ultimately completed the baseline, 3 month, 
and 12 month surveys, and thus were included in the fi-
nal data analyses. Table 2 summarizes the study popula-
tion’s demographics. 
3.2. Composite Heart Health Index 
In order to assess the effectiveness of our intervention, 
we evaluated the mean Composite Heart Health Index 
(CHHI) score between groups. The CHHI was not dif-
ferent at the 12 month time point between the groups 
(intervention 12.8 ± 4.5 points vs control 12.7 ± 4.9 
points, p = 0.9405). 
3.3. Medication Utilization 
Figure 1 illustrates the changes in usage by eligible can-
didates for the four classes of prevention medications for 
the entire cohort. The prescription rate at discharge is 
high in all four groups ranging from 87% for ACEIs/ 
ARBs to 100% for antiplatelet agents. However there are 
significant declines in medication utilization rates for 3 
of the 4 classes with time, first at 3 months and further at 
12 months. There was not a significant difference be-
tween the control and intervention subjects, as shown in 
Figure 2. 
3.4. Knowledge and Motivation Survey 
Figure 3 suggests that there is a high rate of basic under-
standing about CAD, which is present at the time of dis-
charge (after the standard patient education given to all 
patients), and improves significantly over time. Signifi-
cant increases in “motivation” to reduce cardiovascular 
risk from baseline (hospital discharge) to the 3 and 12 
month time periods were noted (see Figure 4). However, 
there were not significant differences between the control 
and intervention groups with respect to the survey re-
sults. 
4. Discussion 
Coronary bypass operations represent an opportunity to 
reinforce the necessity for CAD prevention in patients 
with severe disease [6]. Previous efforts have predomi-
nantly focused on hospital discharge as the optimal time 
to educate patients and establish a preventive regimen. 
However, our study suggests that this alone is not suffi-
cient for sustaining longer-term compliance with the 
preventive regimen. 
4.1. Compliance with Medications over Time 
The current study, documents a clear deficiency in our 
present approach to secondary prevention following 
CABG. Use of 3 of the 4 major classes of preventive 
drugs (ASA, beta blockers, and ACEIs/ARBs) declined 
significantly over time. Despite the fact that several 
studies have documented sub-optimal compliance with 
secondary prevention medications following CABG, 
only a few have examined patterns of use in the longer 
term. Goyal and colleagues found that patients taking 
half or less of the indicated preventive medications suf-
fered significantly higher rates of death or myocardial 
infarction at 2 years following CABG [3]. However, they 
did not show a significant decrement in the utilization of 
indicated medications over time. In this particular study 
only 65% of eligible patients were taking all 4 of the 
suggested classes of medications, and very few changes 
were made before the one year mark. Okrainec and col-
leagues demonstrated no change in compliance with 
preventive medications from the time of hospital dis-
charge to the one year follow up time [10]. The reasons 
for the discrepancy between these studies are our results 
are possibly explained by our high rate of baseline (hos-
pital discharge) medication usage. Additionally, patients 
with medication contraindications at the time of hospital 
discharge no longer possessed these contraindications at 
3 and 12 months postoperatively. This raises the number 
of “eligible” recipients at these time points. Physicians 
caring for post-CABG patients need to routinely screen 
for non-prescribed preventive medications and initiate 
therapy when contraindications are no longer present.  
4.2. Reasons for Noncompliance over Time 
Although it has been documented that patients often fail 
to adhere to medication changes critical for the preven-
ion of future cardiovascular events following CABG, the t 
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Table 2. Demographics. 
 Control (n = 49) Intervention (n = 49) P value
Age in years (mean ± SD) 63.85 ± 8.13 63.88 ± 9.73 0.9883
Male, % 77.6 75.5 0.8116
Black, % 6.4 0 
Hispanic, % 0 2.2 
White, % 72.3 71.7 
Other race, % 6.4 6.5 
Undetermined race, % 14.9 19.6 
0.3726
College educated, % 57.1 57.1 1 
Body mass index, kg/m2 (mean ± SD) 29.6 ± 4.6 30.0 ± 5.1 0.772 
Current tobacco use, % 22.4 20.4 0.914 
History of myocardial infarction, % 19.6 10.4 0.213 
History of hypertension, % 73.9 85.4 0.165 
Preoperative systolic blood pressure, mmHg (mean ± SD) 132 ± 19 128 ± 17 0.2983
History of heart failure, % 13.0 4.2 0.1542
Left ventricular ejection fraction, % (mean ± SD) 53 ± 12 53 ± 14 0.683 
History of diabetes mellitus, % 34.8 31.2 0.7157
History of diabetic nephropathy, % 0 8.3 0.1173
Baseline total cholesterol (mean ± SD) 161 ± 50 162 ± 48 0.8932
Baseline HDL (mean ± SD) 36 ± 14 36 ± 11 0.5646
Baseline LDL (mean ± SD) 98 ± 40 96 ± 37 0.7784
Baseline triglycerides (mean ± SD) 131 ± 74 142 ± 115 0.7805
Risk of mortality, STS Score (mean ± SD) 0.014 ± 0.014 0.011 ± 0.008 0.7453
Risk of renal failure, STS Score (mean ± SD) 0.032 ± 0.034 0.027 ± 0.021 0.3199
Aspirin allergy, % 0 0 1 
Beta blocker allergy, % 0 0 1 
Statin allergy, % 4.4 2.1 0.6129
Statin intolerance, % 2.2 10.4 0.2041
ACEI allergy, % 2.2 4.2 1 
ARB allergy, % 2.2 2.1 1 
Aspirin use, prior to admission, % 80.4 79.2 0.8784
Beta blocker, prior to admission, % 52.2 66.7 0.1523
Statin use, prior to admission, % 65.2 66.7 0.8822
ACEI or ARB use, prior to admission, % 56.5 68.8 0.2202
# secondary prevention medications prior to admission (mean ± SD) 2.4 ± 1.3 2.8 ± 1.1 0.1872
# of CABG (mean ± SD) 3.3 ± 1.1 3.5 ± 1.0 0.6117
Valve surgery in addition to CABG, % 17.4 14.6 0.7102
Cardiopulmonary bypass time, in minutes (mean ± SD) 85 ± 31 87 ± 27 0.7281
Cross clamp time, in minutes (mean ± SD) 70 ± 26 68 ± 25 0.7358
Hospital length of stay in days (mean ± SD) 7.0 ± 2.9 7.2 ± 3.1 0.8549
Postoperative length of stay in days (mean ± SD) 5.6 ± 2.0 5.3 ± 1.8 0.6657
Lowest systolic blood pressure in the 48 hours prior to discharge (mean ± SD) 105 ± 13 108 ± 13 0.2577
Highest systolic blood pressure in the 48 hours prior to discharge (mean ± SD) 138 ± 17 140 ± 15 0.5145
Lowest heart rate in the 48 hours prior to discharge (mean ± SD) 69 ± 10 69 ± 10 0.9404
Highest heart rate in the 48 hours prior to discharge (mean ± SD) 85 ± 11 85 ± 12 0.9353
SD = standard deviation; HDL = high density lipoprotein; LDL = low density lipoprotein; STS = Society of Thoracic Surgeons; ACEI = angiotensin converting 
enzyme inhibitor; ARB = angiotensin II receptor blocker; CABG = coronary artery bypass grafts. 
Secondary Prevention Following Coronary Artery Bypass Surgery: A Pilot Study for Improved Patient Education 291
 
Figure 1. Secondary prevention medication use among eligible patients undergoing CABG (all subjects). 
 
 
Figure 2. Secondary prevention medication use among eligible patients undergoing CABG (by study group). 
 
reasons for such noncompliance are unclear. Previous 
reports have suggested that this might be related to a va-
riety of factors such as patients feeling that medications 
are overused [16]. Our study examined possible explana-
tions for this phenomenon through responses to patient 
urveys done on a serial basis. It must be acknowledged  s   
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Figure 3. Percent of subject responses suggesting positive understanding of coronary artery disease. 
 
 
Figure 4. Percent of subject responses suggesting positive motivation to reduce cardiovascular risk. 
 
that there are many factors impacting compliance with 
evidence-based guidelines, knowledge and motivation 
being only two. Our results indicate that patients do seem 
to acquire significant knowledge about CAD after the 
CABG experience, a finding that supports the effective-
ness of our existing “usual care” protocols. Moreover, 
this enhanced knowledge seems to be well maintained up 
to a year after the operation. Patients also seem to be 
highly motivated to make changes necessary to maintain 
good cardiovascular health at the 3 and 12 months time 
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points following CABG surgery. If patients are more 
knowledgeable and better intentioned to comply with 
long-term preventive measures in the perioperative pe- 
riod, why do rates of medication compliance decline over 
time? We incorrectly hypothesized that a later educa- 
tional “booster”, given during the follow up period sev- 
eral weeks after hospital discharge would be an effective 
way of maintaining the patients’ compliance with pre- 
ventive measures. However, patients cannot take appro- 
priate medications unless their individual physicians 
identify the indications for therapy and prescribe appro- 
priately. Moreover, our interaction with patients suggests 
that the majority are not comfortable asking the physic- 
cian to prescribe certain medications; thus it is incumbent 
upon the prescriber to provide appropriate follow-up and 
medication adjustments over time.  
4.3. Single-Intervention Does Not Seem to 
Improve CV Health 
Even though our educational interventions were very 
well-received by patients and their families who partici- 
pated, clearly more than a single early educational 
“booster” is necessary to reach the goal of optimal long- 
term compliance with prevention protocols. The answer 
to long-term compliance may reside in an ongoing pro- 
gram of interaction between the patient and healthcare 
providers to constantly reinforce goals and maintain a 
preventive regimen. While in the present study, we did 
communicate our recommendations (in writing) to each 
patient’s cardiologist and primary care physician follow- 
ing the intervention; there is no evidence that this af- 
fected prescribing behavior. Further attempts to improve 
utilization and compliance with evidence-based regimens 
must be directed at bringing primary providers and pa- 
tients together such that both groups are fully aware of 
what specifically is required to reduce the risks of further 
cardiovascular events following CABG, and to provide a 
structured system to monitor and augment this process. 
4.4. Study Limitations 
An important consideration is the longitudinal compari- 
sons in our study only involved assessment of prescrib- 
ing, but not adherence to, the four classes of preventive 
cardiovascular drugs. While not validated, our survey 
questions were designed to assess patients’ basic under- 
standing of their disease, medications, and motivation to 
improve their risk of future disease. Subsequent investi- 
gations might consider utilizing validated surveys to im- 
prove study generalizability. Certainly our interventions, 
both pre-discharge and the additional “booster” did em- 
phasize the importance of comprehensive risk factor 
modification, taking into account all of these factors. 
Future efforts should focus more specifically on these 
issues, since they are important components to a risk- 
reduction strategy [11]. Another limitation of this pilot 
study was the fact that it was primarily directed at the 
patient, although a crucial role in prevention is in fact 
played by his/her physician. Even though there was an 
attempt to engage the referring physicians in the process, 
in the form of a written “action plan” developed by the 
booster team, coordination for follow-up will need to be 
more thorough in the future to maximize effectiveness of 
the preventive regimen. 
4.5. Conclusion 
Efforts directed at establishing secondary prevention 
plans for postoperative CABG patients are important, but 
should not be restricted to the time point of hospital dis- 
charge alone or a single early follow-up intervention. 
There is a significant drop-off of secondary prevention 
medication prescribing rates to eligible patients over time. 
This drop-off does not seem to be related to deficiencies 
in either patient knowledge regarding CAD or motivation 
to follow established guidelines and lifestyle modifica- 
tion. Ongoing educational strategies, screening for non- 
prescribed secondary prevention medications, and regu- 
lar follow up must be incorporated to impact long-term 
patient outcomes. Additionally, there is a clear need for 
better systems to insure continuity of care as patients 
transition from the surgical teams back to primary care in 
order to improve evidence-based care.  
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